Investing.com - BioCryst (NASDAQ: BCRX) reported first quarter EPS of $-0.170, $0.04 better than the analyst estimate of $-0.210. Revenue for the quarter came in at $92.76M versus the consensus estimate of $85.82M.
Guidance
BioCryst sees FY 2024 revenue of $390.000M-$400.000M versus the analyst consensus of $395.100M.
BioCryst's stock price closed at $4.45. It is down -16.040% in the last 3 months and down -48.010% in the last 12 months.
BioCryst saw 3 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See BioCryst's stock price’s past reactions to earnings here.
According to InvestingPro, BioCryst's Financial Health score is "good performance".
Check out BioCryst's recent earnings performance, and BioCryst's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar